Reva Medical (ASX:RVA) said yesterday that it won CE Mark approval in the European Union for its Fantom sirolimus-eluting bioresorbable coronary scaffold.
The Fantom scaffold is the San Diego, Calif.-based company’s 1st commercial product. Reva said it plans to begin selling the product in Europe this quarter.
Get the full story at our sister site, Drug Delivery Business News.
The post Reva Medical wins CE Mark for Fantom bioresorbable scaffold appeared first on MassDevice.
from MassDevice http://ift.tt/2oxvzWJ
Cap comentari:
Publica un comentari a l'entrada